Editas Medicine, Inc. (EDIT)
| Market Cap | 300.47M |
| Revenue (ttm) | 40.52M |
| Net Income (ttm) | -160.06M |
| Shares Out | 97.87M |
| EPS (ttm) | -1.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,266,027 |
| Open | 2.880 |
| Previous Close | 2.890 |
| Day's Range | 2.855 - 3.075 |
| 52-Week Range | 1.290 - 4.537 |
| Beta | 2.04 |
| Analysts | Strong Buy |
| Price Target | 4.92 (+60.26%) |
| Earnings Date | May 11, 2026 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ... [Read more]
Financial Performance
In 2025, Editas Medicine's revenue was $40.52 million, an increase of 25.39% compared to the previous year's $32.31 million. Losses were -$160.06 million, -32.49% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for EDIT stock is "Strong Buy." The 12-month stock price target is $4.92, which is an increase of 60.26% from the latest price.
News
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing in vivo CRISPR therapies, with EDIT-401 showing 90% LDL-C reduction in preclinical models and a strong safety profile. Human proof-of-concept data is expected by year-end, targeting high-risk hyperlipidemia patients, and the pipeline includes additional programs leveraging proprietary technology.
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clini...
Editas Medicine Transcript: TD Cowen 46th Annual Health Care Conference
Focused on in vivo CRISPR editing, the lead program aims for human proof of concept by year-end, targeting a 90% LDL cholesterol reduction in high-risk patients. The approach leverages non-coding DNA edits, robust preclinical data, and a scalable LNP platform, with financial runway into Q3 2027.
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Genflow Biosciences PLC Announces Directorate Change
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Editas Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference
A novel CRISPR-based LDLR upregulation strategy achieved a 90% LDL cholesterol reduction in preclinical models, with plans to target HeFH patients first and expand to broader populations. Human proof-of-concept data is expected by end of 2026, and cash runway extends to Q3 2027.
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company...
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Editas Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Industry leaders discussed advances in genome editing, emphasizing the coexistence of diverse editing technologies and the critical role of delivery systems. Commercial success hinges on transformational efficacy, cost-effective delivery, and strategic indication selection, with multiple approvals anticipated in the coming years.
Editas Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference
EDIT-401 targets a 90% LDL cholesterol reduction with a single-dose, durable CRISPR therapy, aiming for IND/CTA filing by mid-2026 and human proof-of-concept by year-end 2026. The program leverages unique upregulation, robust preclinical data, and a strong financial position into Q2 2027.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% ...
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Editas Medicine Transcript: Cantor Global Healthcare Conference 2025
Significant progress was highlighted in advancing in vivo CRISPR editing, with EDIT-401 selected as the lead program targeting LDLR and showing 90% LDL-C reduction in preclinical models. Human proof of concept is targeted by end of 2026, supported by a cash runway into Q2 2027.
Editas Medicine Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
EDIT-401, a one-time in vivo CRISPR therapy, demonstrated a 90% LDL reduction in preclinical models, aiming for human proof of concept by end of 2026. The program targets multiple hyperlipidemia segments, offers strong safety and durability, and is positioned for significant market impact.
Editas Medicine Transcript: Status Update
EDIT-401, a one-time in vivo CRISPR therapy, demonstrated a 90% LDL reduction in preclinical models, positioning it as a potential best-in-class treatment for hyperlipidemia. Human proof of concept data is targeted for late 2026, with strong safety and durability signals observed so far.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into se...
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy...
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalass...
Editas Medicine Transcript: BofA Securities 2025 Healthcare Conference
The session highlighted a sharpened focus on in vivo gene editing, with two lead programs advancing in HSC and liver indications. Recent data show strong preclinical results, and key milestones are set for 2025–2027, supported by a cash runway into Q2 2027.
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice